36
Participants
Start Date
February 29, 2012
Primary Completion Date
October 31, 2012
Study Completion Date
December 31, 2012
Group 1: 10 ug FMP012 with 2 ug GLA-SE
Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
Group 2: 10 ug FMP012 with 5 ug GLA-SE
E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE
E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
Controlled group-Challenged Only: no vaccination
The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
Clinical Trials Center, WRAIR, Silver Spring
United States Agency for International Development (USAID)
FED
Access to Advanced Health Institute (AAHI)
OTHER
U.S. Army Medical Research and Development Command
FED